vs

Side-by-side financial comparison of Alignment Healthcare, Inc. (ALHC) and VEON Ltd. (VEON). Click either name above to swap in a different company.

Alignment Healthcare, Inc. is the larger business by last-quarter revenue ($1.2B vs $1.1B, roughly 1.1× VEON Ltd.). VEON Ltd. runs the higher net margin — 55.9% vs 0.9%, a 55.0% gap on every dollar of revenue. On growth, VEON Ltd. posted the faster year-over-year revenue change (5.8% vs -74.7%).

Alignment Healthcare, Inc. is a U.S.-based healthcare provider offering Medicare Advantage plans for seniors. It adopts a value-based care model, partnering with local providers to deliver personalized coordinated medical services, prescription drug coverage and supplemental benefits to members across multiple U.S. states.

VEON Ltd., also known as VEON Group, is a multinational telecommunication and digital services company. Headquartered in Dubai, the company is publicly traded on the U.S.-based NASDAQ stock exchange. VEON operates in six markets in Europe and Asia, including Bangladesh, Kazakhstan, Kyrgyzstan, Pakistan, Ukraine and Uzbekistan. Specific brands include Banglalink in Bangladesh, Jazz in Pakistan, Kyivstar in Ukraine, and units operating in Kazakhstan, Kyrgyzstan, and Uzbekistan under the Beeline...

ALHC vs VEON — Head-to-Head

Bigger by revenue
ALHC
ALHC
1.1× larger
ALHC
$1.2B
$1.1B
VEON
Growing faster (revenue YoY)
VEON
VEON
+80.6% gap
VEON
5.8%
-74.7%
ALHC
Higher net margin
VEON
VEON
55.0% more per $
VEON
55.9%
0.9%
ALHC

Income Statement — Q1 FY2026 vs Q2 FY2025

Metric
ALHC
ALHC
VEON
VEON
Revenue
$1.2B
$1.1B
Net Profit
$11.4M
$608.0M
Gross Margin
Operating Margin
75.4%
Net Margin
0.9%
55.9%
Revenue YoY
-74.7%
5.8%
Net Profit YoY
583.1%
EPS (diluted)
$0.34

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ALHC
ALHC
VEON
VEON
Q1 26
$1.2B
Q4 25
$1.0B
Q3 25
$993.7M
Q2 25
$1.0B
$1.1B
Q1 25
$926.9M
Q4 24
$701.2M
Q3 24
$692.4M
Q2 24
$681.3M
$1.0B
Net Profit
ALHC
ALHC
VEON
VEON
Q1 26
$11.4M
Q4 25
$-11.0M
Q3 25
$3.7M
Q2 25
$15.7M
$608.0M
Q1 25
$-9.1M
Q4 24
$-31.1M
Q3 24
$-26.4M
Q2 24
$-24.0M
$89.0M
Operating Margin
ALHC
ALHC
VEON
VEON
Q1 26
Q4 25
-1.0%
Q3 25
0.8%
Q2 25
2.2%
75.4%
Q1 25
-0.6%
Q4 24
-3.2%
Q3 24
-2.8%
Q2 24
-2.7%
27.1%
Net Margin
ALHC
ALHC
VEON
VEON
Q1 26
0.9%
Q4 25
-1.1%
Q3 25
0.4%
Q2 25
1.5%
55.9%
Q1 25
-1.0%
Q4 24
-4.4%
Q3 24
-3.8%
Q2 24
-3.5%
8.7%
EPS (diluted)
ALHC
ALHC
VEON
VEON
Q1 26
Q4 25
$-0.04
Q3 25
$0.02
Q2 25
$0.07
$0.34
Q1 25
$-0.05
Q4 24
$-0.15
Q3 24
$-0.14
Q2 24
$-0.13
$0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ALHC
ALHC
VEON
VEON
Cash + ST InvestmentsLiquidity on hand
$705.6M
$1.3B
Total DebtLower is stronger
Stockholders' EquityBook value
$206.9M
$1.5B
Total Assets
$1.3B
$8.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ALHC
ALHC
VEON
VEON
Q1 26
$705.6M
Q4 25
$604.2M
Q3 25
$644.1M
Q2 25
$503.8M
$1.3B
Q1 25
$479.5M
Q4 24
$470.6M
Q3 24
$381.0M
Q2 24
$363.7M
$862.0M
Total Debt
ALHC
ALHC
VEON
VEON
Q1 26
Q4 25
$323.2M
Q3 25
$322.7M
Q2 25
$322.3M
Q1 25
$321.9M
Q4 24
$321.4M
Q3 24
$212.0M
Q2 24
$211.7M
Stockholders' Equity
ALHC
ALHC
VEON
VEON
Q1 26
$206.9M
Q4 25
$179.3M
Q3 25
$161.9M
Q2 25
$141.0M
$1.5B
Q1 25
$108.1M
Q4 24
$99.9M
Q3 24
$114.5M
Q2 24
$123.7M
$1.1B
Total Assets
ALHC
ALHC
VEON
VEON
Q1 26
$1.3B
Q4 25
$1.1B
Q3 25
$1.1B
Q2 25
$1.0B
$8.5B
Q1 25
$895.6M
Q4 24
$782.1M
Q3 24
$692.3M
Q2 24
$716.3M
$7.3B
Debt / Equity
ALHC
ALHC
VEON
VEON
Q1 26
Q4 25
1.80×
Q3 25
1.99×
Q2 25
2.29×
Q1 25
2.98×
Q4 24
3.22×
Q3 24
1.85×
Q2 24
1.71×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ALHC
ALHC
VEON
VEON
Operating Cash FlowLast quarter
$128.7M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
11.27×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ALHC
ALHC
VEON
VEON
Q1 26
$128.7M
Q4 25
$-50.4M
Q3 25
$144.6M
Q2 25
$29.1M
Q1 25
$16.6M
Q4 24
$-8.7M
Q3 24
$26.2M
Q2 24
$23.5M
Free Cash Flow
ALHC
ALHC
VEON
VEON
Q1 26
Q4 25
$-55.4M
Q3 25
$139.1M
Q2 25
$21.1M
Q1 25
$8.4M
Q4 24
$-18.0M
Q3 24
$16.9M
Q2 24
$11.8M
FCF Margin
ALHC
ALHC
VEON
VEON
Q1 26
Q4 25
-5.5%
Q3 25
14.0%
Q2 25
2.1%
Q1 25
0.9%
Q4 24
-2.6%
Q3 24
2.4%
Q2 24
1.7%
Capex Intensity
ALHC
ALHC
VEON
VEON
Q1 26
Q4 25
0.5%
Q3 25
0.6%
Q2 25
0.8%
Q1 25
0.9%
Q4 24
1.3%
Q3 24
1.3%
Q2 24
1.7%
Cash Conversion
ALHC
ALHC
VEON
VEON
Q1 26
11.27×
Q4 25
Q3 25
38.77×
Q2 25
1.86×
Q1 25
Q4 24
Q3 24
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons